GLOBAL BIOENERGIES successfully carries out a private placement of approximately €10.25 million

GLOBAL BIOENERGIES successfully carries out a private placement of approximately €10.25 million

Evry, 30 June 2017 Global Bioenergies (Alternext Paris: ALGBE), (the “Company”), today announced the successful completion of a Private Placement with qualified French and international investors. The Company has placed 640,00 new shares of a nominal unit value of €0.05, at a unit price of €16.00, inclusive of the share premium, for a total amount of approximately €10.25 million, representing 17.48% of the Company’s share capital.

For information, the stake of a shareholder holding 1% of the Company’s share capital prior to the issue will be brought to 0.85%.

The proceeds will be used to complete the development and the industrialisation of the Isobutene process, finance the detailed engineering studies of the IBN-One plant, launch the commercial roll-out and further diversify the raw materials available to the process.

Marc Delcourt, CEO of Global Bioenergies, declares: “I particularly wish to thank CM-CIC Investissement, our historical shareholder, for confirming their trust in us. Its contribution has been a key factor in the success of this operation. The proceeds bring our un-audited cash position to 19 million euros. They will enable the Company to fully transition to the commercial phase and to face up to its financial needs over the coming 24 months”.

The principle and the execution of the transaction were approved by Board resolutions dated 29 June 2017 and 30 June 2017, in accordance with the authority granted to it by the eighth resolution of the Combined General Meeting of Shareholders on 26 June 2017. The subscription price represents a discount of 18.61% over the volume weighted average Company share price in the last three trading sessions prior to the issue.

The share capital increase is carried out through the issue of ordinary shares, without preferential subscription rights, by Private Placement for qualified investors in accordance with Article L.411-2 II of the French Monetary and Financial Code (Code monétaire et financier). The new shares will carry entitlement to dividend rights and will be admitted to trading on the Euronext Paris Alternext market under ISIN code FR0011052257 – ALGBE. On settlement and delivery of the shares, the Company’s share capital will comprise 4.301.977 shares.

The distribution of the Company’s equity following the Private Placement has thus significantly evolved.

Before operation

After operation

Marc DELCOURT

358 860

9,80%

358 860

8,34%

Philippe MARLIERE

358 635

9,79%

358 635

8,34%

SEVENTURE PARTNERS

670 296

18,30%

670 296

15,58%

CM-CIC innovation & Investissement

363 129

9,92%

422 304

9,82%

Free-float

1 911 057

52,19%

2 491 882

57,92%

Including Keren

0,00%

213 010

4,95%

3 661 977

100%

4 301 977

100

It is reminded that Global Bioenergies had announced the suspension of the structured financing with Bracknor in press releases dated May 18th and June 26th 2017. The final tranche will be emitted on July 26th 2017.

The Private Placement is being conducted by Sponsor Finances and Midcap Partners as joint advisors and bookrunners. The issue does not require registration with the French financial markets authority (AMF) or publication of a prospectus.

In line with article 211-3 of the “Règlement general de l’Autorité des marchés financiers”, the placement of Company’s shares in the context of the present capital increase carried out with a defined category of beneficiaries has not required the submission of a prospectus subject to approval by the financial markets authority. Detailed information concerning the Company and notably concerning its activity, its results and associated risk factors, are presented in the annual financial report covering the period ending December 31 2016 which is available, as well as other regulated information and all the Company’s press releases, on its web site (www.globalbioenergies-invest.com)

Legal notice

Securities may only be offered for sale or sold in the United States following registration under the terms of the U.S. Securities Act of 1933, as amended, or within the framework of an exemption from registration. The Company’s securities covered by this press release have not been and will not be registered under the U.S. Securities Act and the Company does not intend to issue a public offering of the securities which are the subject of this press release in the United States.

About GLOBAL BIOENERGIES

Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performances of its process, operates its industrial pilot, has started operations at its demo plant in Germany, and prepares the first full-scale plant through a Joint-Venture with Cristal Union, named IBN-One. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 – ALGBE), and is part of the Alternext Oseo Innovation index.

Should you like to be kept informed, subscribe to our news feed on www.global-bioenergies.com

Contacts

GLOBAL BIOENERGIES

François-Henri Reynaud

Chief Financial Officer

Phone: +33 (0)1 64 98 20 50

Email: invest@global-bioenergies.com

0 Comments